SOLAR IS THE FIRST HEAD-TO-HEAD SWITCH STUDY COMPARING EVERY-2-MONTH VOCABRIA + REKAMBYS WITH DAILY ORAL THERAPY
SOLAR explored virological suppression, safety and tolerability, as well as patient treatment experiences with every-2-month VOCABRIA + REKAMBYS vs daily oral therapy with BIC/FTC/TAF
- No history of non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), C-C Chemokine receptor 5 or other entry inhibitors
- Must be on the uninterrupted current regimen of BIC/FTC/TAF for ≥6 months prior to screening with an undetectable HIV-1 viral load for ≥6 months prior to screening. BIC/FTC/TAF must be the patient’s first or second regimen. If it is their second regimen, their previous regimen must have been integrase inhibitor (INI)-based
- History of virologic failure
- Known or suspected presence of resistance mutations to the individual components of BIC/FTC/TAF, cabotegravir and rilpivirine
- Hepatitis B virus (HBV) infection at screening
- Moderate to severe hepatic impairment
- Women who were pregnant or breastfeeding or planned to become pregnant or breastfeed
of participants on BIC/FTC/TAF (N=670) reported always or often experiencing at least one of the following psychological challenges:
Worried about people unintentionally discovering their HIV status
Worried about forgetting to take their HIV medication
Felt that taking their HIV medication was an uncomfortable reminder of their HIV status
- Ramgopal MN, Castagna A, Cazanave C, et al. SOLAR 12-Month Results – Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF. Presented at Conference on Retroviruses and Opportunistic Infections (CROI): February 19–22, 2023. REF-182990.
- A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVYR (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR). 2022. www.clinicaltrials.gov/ct2/show/NCT04542070. REF-182394. Accessed January 30, 2023.
REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.